|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 New York Avenue NW |
Address2 | Suite 600 |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401049961-12
|
||||||||
|
6. House ID# 422720000
|
||||||||
| TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Paul Ehrlich |
Date | 10/20/2016 4:24:27 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017;
P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029);
H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act;
Other Labor, Health and Human Services Appropriations (no bills introduced);
S. 1413, FDA User Fee Protection Act;
FDAs Changes Being Effected Rule;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Daniel |
Bachner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015;
S. 1878, Advancing Hope Act of 2015;
S. 632, STRONG Patents Act of 2015;
H.R. 9, Innovation Act;
S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016;
H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015;
H.R. 5573 & S. 3094, Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act;
S. 3056, CREATES Act of 2016;
Proposals/Initiatives related to international intellectual property protection;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Daniel |
Bachner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 6, 21st Century Cures Act;
S. 2700, FDA and NIH Workforce Authorities Modernization Act;
Discussions to clarify or reform the 340B program;
Biologics Price Competition and Innovation Act;
H.R. 1101 & S. 1287, Viral Hepatitis Testing Act;
Public Law 111-148, The Patient Protection and Affordable Care Act;
H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015;
Proposals to address prescription drug abuse;
Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA);
Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA);
H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies;
H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015;
H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015;
S. 524, Comprehensive Addiction and Recovery Act of 2016;
H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016;
H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016;
H.R. 6174, Closing Loopholes for Orphan Drugs Act;
S.3239, RACE for Children Act;
Expanded Access (legislation not introduced);
H.R. 4207, Medicare Fair Drug Pricing Act of 2015;
Clinton's 1993 Health Security Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Policies to enhance patient access to medicines in Medicaid;
Policies to enhance patient access to medicines in Medicare;
H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act;
H.R. 2914, Promoting Integrity in Medicare Act;
H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015
H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act;
H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015;
H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act;
H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models;
Medicare payment proposals (MedPAC);
Medicare Access and CHIP Reauthorization Act (MACRA);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Ford |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
Michael |
Boyd |
|
|
|
Stephen |
Scango |
|
|
|
Daniel |
Bachner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Administrations Tax Reform and 2015 Budget Proposals;
Senate and House Committee Tax Reform Proposals;
H.R. 5278, PROMESA;
Puerto Rican Economy and Debt Relief Proposals (no bills introduced);
Proposals to reform domestic and international tax structures (no bills introduced);
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
Andrew |
Kaplan |
|
|
|
Heather |
Strawn |
|
|
|
John |
Ford |
|
|
|
Daniel |
Bachner |
|
|
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Atlantic Trade and Investment Partnership;
Trans-Pacific Partnership Agreement;
Colombia OECD Accession;
Renewed engagement possibilities with Argentina;
Colombia Special 301 Out-of-Cycle Review;
Saudi Arabia recent developments report to USTR;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Boyd |
|
|
|
Steven |
Scango |
|
|
|
Heather |
Strawn |
|
|
|
John |
Ford |
|
|
|
Daniel |
Bachner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |